News and Trends 28 Jul 2022 Step Pharma moves into oncology clinical trials Step Pharma, which works on CTPS1 inhibition for the targeted treatment of cancer, has announced its lead asset STP938 has cleared both an Investigational New Drug (IND) application by the Food and Drug Administration (FDA), and a clinical trial application (CTA) by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). This means Step Pharma […] July 28, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2022 AbbVie seeks nod from FDA and EMA for Crohn’s disease drug U.S. biopharma company AbbVie has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ) for the treatment of adult patients with moderately to severely active Crohn’s disease. “Crohn’s disease can be debilitating and have a significant impact on a person’s daily life,” […] July 27, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2022 T-cell therapy company AlloVir set to raise $126.6M AlloVir, Inc., a late clinical-stage allogeneic T-cell immunotherapy company, has entered into a securities purchase agreement with a group of institutional and strategic investors to sell 27,458,095 shares of common stock in a registered direct offering at a purchase price of $4.61 per share. Gross proceeds from the offering will equal approximately $126.6 million. The […] July 27, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2022 Diffusion Pharmaceuticals to start brain tumor clinical trial U.S. biopharma company Diffusion Pharmaceuticals Inc. is set to start a new phase 2 clinical trial. Entitled “Open-Label, Dose-Escalation, Phase 2 Safety and Efficacy Study of TSC in Newly Diagnosed Glioblastoma (GBM) Patients when Administered with Standard of Care (“SOC”),” the company said the trial is a result of a collaboration with the United States […] July 27, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2022 SOTIO Biotech starts solid tumor trial SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group is starting its phase 2 trial on patients with selected advanced/refractory solid tumors. The company has dosed its first patient in the AURELIO-04 combination trial of SOT101 and MSD’s (Merck & Co., Inc., Rahway, NJ) anti-PD-1 therapy KEYTRUDA (pembrolizumab). “The initiation of this phase […] July 27, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2022 Oryzon collaborating with CMT Research Foundation in the US Spanish biopharma company Oryzon Genomics, S.A. is starting a preclinical collaboration with the CMT Research Foundation (CMTRF), a U.S.-based patient-led, non-profit organization focused on delivering treatments and cures for Charcot-Marie-Tooth (CMT) disease, to explore Oryzon’s histone deacetylase 6 (HDAC6) inhibitors. HDAC6 inhibitors have been previously described as potentially effective treatments for CMT. Oryzon has recently […] July 27, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2022 Pleco Therapeutics expands into U.S. and names president Pleco Therapeutics BV, a biopharmaceutical company based in the Netherlands, has expanded, with the incorporation of a U.S. subsidiary, Pleco Therapeutics USA. Pleco Therapeutics, which develops novel treatments designed to detoxify the cancer promoting cellular micro-environment, also named Michael Stalhamer as the US subsidiary’s president and first employee. Stalhamer also serves on the global leadership […] July 26, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2022 Irish agritech start-up CropBiome receives €1.3M investment Irish agritech startup CropBiome, a joint University College Dublin (UCD) and Trinity College Dublin (TCD) spin-out, has received €1.3 million ($1.3 million) funding. HBAN (Halo Business Angel Network), the all-island organization responsible for the promotion of business angel investment, and a joint initiative of Enterprise Ireland, InterTradeIreland and Invest Northern Ireland, participated in the oversubscribed […] July 26, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2022 Oxford Biomedica sets up new project and signs LSA Oxford Biomedica plc, a UK-based gene and cell therapy group, has initiated a new project with Orchard Therapeutics utilizing the company’s LentiStable technology. The group also announced the signing of a new licence and supply agreement (LSA) with an undisclosed US-based private biotech company advancing a new generation of adoptive cell therapies. LentiStable technology As […] July 26, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2022 Catalonia health startup investments in 2022 top €296M to overtake 2021 tally Life sciences organization Biocat says midyear investment in startups in the BioRegion of Catalonia in Spain is 2.5 times higher than the same period last year, at €296 million ($301 million). The total for the entire year 2021 was €238 million ($242 million). The first semester included a round of €100 million ($101.8 million) by […] July 26, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2022 Valo Therapeutics acquires PeptiCHIP technology to identify tumor antigens Finnish immunotherapy company Valo Therapeutics Oy (ValoTx) has obtained exclusive licensing of intellectual property rights (IPR) from the University of Helsinki, Finland, for the institution’s PeptiCHIP technology. Following further validation by ValoTx, and the achievement of specific milestones, the IPR will transfer in full to the company. Valo said the deal will enable the rapid […] July 26, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2022 Ginkgo acquires Zymergen for $300M and picks up Bayer facility for $83M U.S. cell programming company Ginkgo Bioworks has signed definitive agreements to acquire two teams and technologies. The deals are with Bayer and Zymergen. Bayer transaction The company confirmed the previously announced transaction with Bayer to expand Ginkgo’s platform capabilities in agricultural biologicals. Ginkgo will acquire Bayer’s 175,000-square-foot West Sacramento Biologics Research & Development site, team, […] July 26, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email